Evaluation of the time to clinical recovery in the case with indomethacin in moderate-intensity pneumonia caused by Corona 19 compared with the control group
Randomized single blind, phase 3 clinical trial on 60 patients, The random number table was used for randomization
Settings and conduct:
This study was performed in two hospitals, Noor and Amin, in Isfahan, on patients with moderate-intensity pneumonia caused by covid 19.
Participants/Inclusion and exclusion criteria:
18- to 75-year-olds with moderate-intensity pneumonia caused by Covid 19 whose disease has been proven on the basis of CT scan or PCR evidence and have signed a participation form.
All people who are prohibited from taking indomethacin or similar compounds or who are likely to have severe side effects if taken indomethacin
Patients with inclusion criteria in the intervention group, in addition to the usual treatment, are treated daily with indomethacin 75 mg slow-release tablets for 5 consecutive days. In the control group, placebo is added to the usual treatment for covid 19 infection.
Main outcome variables:
Time to clinical recovery
14 days readmission Rate
Time to intubation
28 days survival rate
side effects caused by indomethacin